

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 50  
 ICB commissioned 13  
 Non-ICB commissioned 23  
 Not applicable 14  
 ICB commissioned and approved 5 (38%)  
 Average days to compliance 61

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) [TA879]</a>	Terminated appraisal	06/04/2023	TA					N/A	Terminated appraisal
<a href="#">Tezepelumab for treating severe asthma [TA880]</a>	Recommended	20/04/2023	TA	19/07/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments [TA881]</a>	Not recommended	03/05/2023	TA					N/A	Not recommended
<a href="#">Voclosporin with mycophenolate mofetil for treating lupus nephritis [TA882]</a>	Recommended	03/05/2023	TA	01/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [TA883]</a>	Not recommended	03/05/2023	TA					N/A	Not recommended
<a href="#">Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) [TA884]</a>	Terminated appraisal	03/05/2023	TA					N/A	Terminated appraisal
<a href="#">Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer [TA885]</a>	Recommended	03/05/2023	TA	01/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy [TA886]</a>	Recommended	10/05/2023	TA	08/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer [TA887]</a>	Recommended	10/05/2023	TA	08/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Risankizumab for previously treated moderately to severely active Crohn's disease [TA888]</a>	Recommended	21/08/2023	TA (EAMS)	20/09/2023	ICB	19/09/2023	29	Commissioned by ICBs for adults and by NHS England for people aged 16 to 17 years. 30-day implementation period applies after TA publication or the date that the on-body device receives CE marking, whichever is later.	Red statement. TA published 17/05/2023 but 30-day implementation period only started when the on-body device received CE marking on 21/08/2023.

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Ciltacabtagene autoleucl for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA889]</a>	Terminated appraisal	17/05/2023	TA					N/A	Terminated appraisal
<a href="#">Difelikefalin for treating pruritus in people having haemodialysis [TA890]</a>	Recommended	17/05/2023	TA	15/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia [TA891]</a>	Recommended	31/05/2023	TA	29/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TA892]</a>	Not recommended	31/05/2023	TA					N/A	Not recommended
<a href="#">Brexucabtagene autoleucl for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [TA893]</a>	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF.	NHS England
<a href="#">Axicabtagene ciloleucl for treating relapsed or refractory follicular lymphoma [TA894]</a>	Not recommended	07/06/2023	TA					N/A	Not recommended
<a href="#">Axicabtagene ciloleucl for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy [TA895]</a>	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF.	NHS England
<a href="#">Bulevirtide for treating chronic hepatitis D [TA896]</a>	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma [TA897]</a>	Recommended	06/06/2023	TA	04/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer [TA898]</a>	Recommended	14/06/2023	TA	12/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) [TA899]</a>	Terminated appraisal	06/06/2023	TA					N/A	Terminated appraisal
<a href="#">Tixagevimab plus cilgavimab for preventing COVID-19 [TA900]</a>	Not recommended	14/06/2023	TA					N/A	Not recommended
<a href="#">Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) [TA901]</a>	Terminated appraisal	20/06/2023	TA					N/A	Terminated appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [TA902]</a>	Recommended	21/06/2023	TA	19/09/2023	ICB	19/09/2023	90	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Amber recommended statement
<a href="#">Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [TA903]</a>	Recommended	21/06/2023	TA	19/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer [TA904]</a>	Recommended	21/06/2023	TA	19/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Upadacitinib for previously treated moderately to severely active Crohn's disease [TA905]</a>	Recommended	21/06/2023	TA (Cost comparison)	21/07/2023	ICB	18/07/2023	27	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
<a href="#">Deucravacitinib for treating moderate to severe plaque psoriasis [TA907]</a>	Recommended	28/06/2023	TA	26/09/2023	ICB	19/09/2023	83	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
<a href="#">Rimegepant for preventing migraine [TA906]</a>	Recommended	05/07/2023	TA	03/10/2023	ICB	19/09/2023	76	Rimegepant is commissioned by integrated care boards. Providers are NHS hospital trusts or primary care practitioners, possibly with specialist involvement through shared care agreements or advice and guidance (please see primary care approach section in the guidance).	Amber retained statement
<a href="#">Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy [TA908]</a>	Recommended	05/07/2023	TA	03/10/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	
<a href="#">Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [TA909]</a>	Not recommended	12/07/2023	TA					N/A	Not recommended
<a href="#">Semaqlutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) [TA910]</a>	Terminated appraisal	13/07/2023	TA					N/A	Terminated appraisal
<a href="#">Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer [TA911]</a>	Recommended	26/07/2023	TA	24/10/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. The resource impact of selpercatinib will be covered by the Cancer Drugs Fund budget.	NHS England
<a href="#">Cipaqlucosidase alfa with miglustat for treating late-onset Pompe disease [TA912]</a>	Recommended	15/08/2023	TA	13/11/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [TA913]</a>	Recommended	06/09/2023	TA	05/12/2023	Non-ICB			This technology is commissioned by NHS England. Providers are specialist cardiac centres.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Semaglutide for managing overweight and obesity [TA875]</a>	Recommended	04/09/2023	TA	03/12/2023	ICB			Commercial availability of product confirmed by company on 04 September 2023. NICE subsequently updated the TA recommendations to include the list price of semaglutide and refer to the company's commercial arrangement. This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and specialist weight management services outside of secondary care (e.g. community specialist weight management services).	Red statement
<a href="#">Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency [TA914]</a>	Recommended	20/09/2023	TA	19/12/2023	Non-ICB			Pembrolizumab is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Pegunigalsidase alfa for treating Fabry disease [TA915]</a>	Recommended	04/10/2023	TA	02/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Bimekizumab for treating active psoriatic arthritis [TA916]</a>	Recommended	04/10/2023	TA	02/01/2024	ICB			Bimekizumab is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG
<a href="#">Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [TA917]</a>	Recommended	25/10/2023	TA	23/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Bimekizumab for treating axial spondyloarthritis [TA918]</a>	Recommended	11/10/2023	TA	09/01/2024	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
<a href="#">Rimegepant for treating migraine [TA919]</a>	Recommended	18/10/2023	TA	16/01/2024	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts or primary care practitioners.	Temporary amber recommended statement
<a href="#">Tofacitinib for treating active ankylosing spondylitis [TA920]</a>	Recommended	18/10/2023	TA	16/01/2024	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG
<a href="#">Ruxolitinib for treating polycythaemia vera [TA921]</a>	Recommended	18/10/2023	TA	16/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Daridorexant for treating long-term insomnia [TA922]</a>	Recommended	18/10/2023	TA	16/01/2024	ICB			This technology is commissioned by integrated care boards. Providers are NHS primary care services, expected to be mainly GPs.	Green statement

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) [TA923]</a>	Terminated appraisal	18/10/2023	TA					N/A	Terminated appraisal
<a href="#">Tirzepatide for treating type 2 diabetes [TA924]</a>	Recommended	25/10/2023	TA	23/01/2024	ICB			This technology is commissioned by integrated care boards. Providers are primary care.	Green statement
<a href="#">Mirikizumab for treating moderately to severely active ulcerative colitis [TA925]</a>	Recommended	25/10/2023	TA	23/01/2024	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG
<a href="#">Baricitinib for treating severe alopecia areata [TA926]</a>	Not recommended	25/10/2023	TA					N/A	Black RAG
<a href="#">Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [TA927]</a>	Recommended	25/10/2023	TA	23/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England